150 related articles for article (PubMed ID: 34210494)
1. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
Helfand BT; Xu J
Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
[TBL] [Abstract][Full Text] [Related]
2. Germline testing for prostate cancer prognosis: implications for active surveillance.
Helfand BT; Xu J
Can J Urol; 2019 Oct; 26(5 Suppl 2):48-49. PubMed ID: 31629432
[TBL] [Abstract][Full Text] [Related]
3. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
[TBL] [Abstract][Full Text] [Related]
4. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
5. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
Brady L; Newcomb LF; Zhu K; Zheng Y; Boyer H; Sarkar N; McKenney JK; Brooks JD; Carroll PR; Dash A; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; Morgan TM; Thompson IM; Wagner AA; Pritchard CC; Lin DW; Nelson PS
Cancer Med; 2022 Nov; 11(22):4332-4340. PubMed ID: 35467778
[TBL] [Abstract][Full Text] [Related]
6. Short-Term Outcomes of Active Surveillance for Low Risk Prostate Cancer among Men with Germline DNA Repair Gene Mutations.
Halstuch D; Ber Y; Kedar D; Golan S; Baniel J; Margel D
J Urol; 2020 Oct; 204(4):707-713. PubMed ID: 32191583
[TBL] [Abstract][Full Text] [Related]
7. Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.
Kearns JT; Lapin B; Wang E; Roehl KA; Cooper P; Catalona WJ; Helfand BT
Eur Urol; 2016 Feb; 69(2):223-8. PubMed ID: 26411806
[TBL] [Abstract][Full Text] [Related]
8. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
[TBL] [Abstract][Full Text] [Related]
9. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
Loeb S; Giri VN
Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
[TBL] [Abstract][Full Text] [Related]
11. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Predisposition.
Bhanji Y; Isaacs WB; Xu J; Cooney KA
Urol Clin North Am; 2021 Aug; 48(3):283-296. PubMed ID: 34210485
[TBL] [Abstract][Full Text] [Related]
13. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
14. Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
Xu J; Isaacs WB; Mamawala M; Shi Z; Landis P; Petkewicz J; Wei J; Wang CH; Resurreccion WK; Na R; Bhanji Y; Novakovic K; Walsh PC; Zheng SL; Helfand BT; Pavlovich CP
Prostate; 2021 Jul; 81(10):703-709. PubMed ID: 33956350
[TBL] [Abstract][Full Text] [Related]
15. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
[TBL] [Abstract][Full Text] [Related]
18. Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
Pritchard CC
Can J Urol; 2019 Oct; 26(5 Suppl 2):24-26. PubMed ID: 31629422
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
20. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
